Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Secondary Breast and Bowel Cancers Found to Grow By Piggy-backing on Patients’ Blood Vessels

(ICR [UK]) Oct 18, 2016 - New research into breast and bowel cancers that have spread to the liver shows that some tumours power their growth using pre-existing blood vessels rather than developing new ones.
read article 



This New Nanotechnology Could Become the Next Major Cancer Breakthrough

(FORTUNE) Oct 19, 2016 - It appeared to stop breast cancer from spreading in mice. A breakthrough technology that harnesses manmade nanoparticles could one day become an important new weapon in the fight against cancer.
read article 



High-intensity Interval Training In Patients With Operable NSCLC Improved Aerobic Performance

(IASLC) Oct 19, 2016 - Preoperative high-intensity interval training (HIIT) in patients with resectable non-small cell lung cancer (NSCLC) improved aerobic performance in patients but failed to reduce early complications after tumor resection.
read press release 



Removal of Lobe Instead of Total Thyroid May Benefit Patients after a Suspicious Biopsy for Papillary Thyroid Cancer

(American College of Surgeons) Oct 19, 2016 - Lobectomy is less expensive but more clinically effective than total thyroidectomy. Most Americans with thyroid cancer have an operation to remove the thyroid gland, but those with a smaller, less-threatening form of thyroid cancer may be missing out on a less extensive, less costly, and safer operation that’s actually more effective in treating their cancer, according to study results presented at the 2016 Clinical Congress of the American College of Surgeons.
read press release 



Myomectomies Decline After FDA Crackdown on Morcellation

(Medscape Medical News) Oct 19, 2016 - Rates of myomectomy decreased by almost 64% after the US Food and Drug Administration (FDA) issued a communication warning against the use of laparoscopic power morcellation, according to a new study.
read article (free registration required) 



One-third of Women Treated for Breast Cancer Are Not Getting Appropriate Breast Imaging Follow-up Exam, New Study Finds

(American College of Surgeons) Oct 19, 2016 - An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren’t receiving this follow-up exam, according to new findings presented at the 2016 Clinical Congress of the American College of Surgeons.
read press release 



Pre-Teens Need Just Two Doses of HPV Vaccine, Not Three: Feds

(NBC News) Oct 19, 2016 - There's good news for kids who haven't received all their HPV vaccines yet - they only need two doses of the vaccine instead of three, federal government advisers said Wednesday.
read article 



FDA Grants Accelerated Approval to New Treatment for Advanced Soft Tissue Sarcoma

(FDA.org) Oct 19, 2016 - The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues.
read press release 



Roche Bid for Avastin Follow-on Suffers Blow with Trial Failure

(Reuters) Oct 20, 2016 - Swiss drugmaker Roche's bid to follow its blockbuster cancer drug Avastin with a newer, better drug took a hit when it announced on Thursday that an investigational therapy had failed in a study against metastatic colorectal cancer (mCRC).
read article 



FDA Approves Lilly's LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma

(Lilly) Oct 19, 2016 - LARTRUVO, in combination with doxorubicin, is the first FDA-approved front-line therapy for soft tissue sarcoma in four decades; the approval was based on results from the positive Phase 2 JGDG trial; LARTRUVO received the FDA's Breakthrough Therapy Designation and was approved under the Agency's Accelerated Approval program.
read corporate press release 



Preteens Need Only 2 HPV Shots _ Not 3, CDC Says

(ABC News/Associated Press) Oct 19, 2016 - It's now easier for preteens to get the cervical cancer vaccine. The government on Wednesday quickly adopted a recommendation that preteens get two shots instead of three and space them further apart. Health officials hope that will boost the number of girls and boys who get vaccinated.
read article 



10 Infant Deaths May Be Related to Teething Remedies, F.D.A. Says

(New York Times) Oct 18, 2016 - The Food and Drug Administration is investigating 10 infant deaths that may be related to use of homeopathic teething gels and tablets.
read article 



Celgene Skips the Placebo, Fails Drug Development 101

(TheStreet) Oct 19, 2016 - Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
read article 



Group Proposes 11 Things States Can Do To Curb High Drug Prices

(KHN Morning Briefing) Oct 19, 2016 - News outlets report on stories related to pharmaceutical drug pricing.
read article 



Health Care Likely To Get Turn In Debate Spotlight

(Politico/Politico Pulse) Oct 19, 2016 - Tonight's debate could be another prime-time moment for health care.
read article 



Accurexa, StemImmune Partner to Develop Cancer Immunotherapy

(Genetic Engineering & Biotechnology News) Oct 17, 2016 - Accurexa will partner with StemImmune to develop its stem cell-mediated cancer immunotherapy, the companies said today, through a collaboration whose value was not disclosed.
read article 



EU Green Light For Shire’s Pancreatic Cancer Drug Onivyde

(PharmaTimes [UK]) Oct 19, 2016 - The European Medicines Agency has now issued a green light for Shire's pancreatic therapy Onivyde, following its US approval in July this year.
read article 



ASCO’s Quality Training Program Shifts to a Regional Setting; Applications Now Open for 2017

(ASCO in Action) Oct 16, 2016 - On Oct. 17, applications opened for ASCO’s 2017 Quality Training Program. For 2017, the program, which began three years ago, is shifting its model of in-person sessions at ASCO headquarters in Alexandria, Va., to regional settings.
read article 



ASCO Commends Vice President Biden, Cancer Moonshot Task Force for Contribution to Accelerating Progress Against Cancer

(ASCO) Oct 17, 2016 - Statement by ASCO President Daniel F. Hayes, MD, FACP, FASCO.
read press release 



Apply for ASCO Health Policy Fellowship to Improve Skills Needed to Shape Cancer Policy

(ASCO in Action) Oct 18, 2016 - On October 19, ASCO will begin accepting applications for its prestigious Health Policy Fellowship, a one-year fellowship opportunity designed to give early-career oncologists the unique skills necessary to monitor and shape the regulatory and legislative policies that directly affect the practice environment and impact patients with cancer and their care teams.
read article 



ONC Offers Advice on Purchasing EHR Systems

(ASCO in Action) Oct 17, 2016 - On September 26, the Office of the National Coordinator (ONC) for HIT issued a contracting guide offering physicians advice on negotiating contracts with electronic health record venders in hopes of giving doctors more control over health data.
read article 



ASH Comments on MACRA Final Rule

(ASH) Oct 19, 2016 - Summary of ASH MACRA comments v MACRA final rule.
read article 



Time to Reassess the Cancer Compendia for Off-label Drug Coverage in Oncology

(The JAMA Network/Viewpoint) Oct 18, 2016 - Use of cancer therapies for indications not approved by the US Food and Drug Administration (FDA), also known as “off-label” use, is widely practiced in oncology care.
read article 



New Drug Targets May Boost Protein Inhibitor, Survival for Lung Cancer Patients, Moffitt Cancer Center Study Shows

(Moffitt Cancer Center) Oct 18, 2016 - In a study published today in Science Signaling, Moffitt Cancer Center researchers used proteomics to identify potential drug targets that could boost ALK inhibitors and improve patient outcomes.
read press release 



Study Shows Why Prostate Cancer Cells Develop Resistance To Treatment

(University of York [UK]) Oct 18, 2016 - A new study at the University of York has shown that a standard hormone supplement, used to boost energy levels in prostate cancer patients following radiotherapy, could potentially increase the chances of the cancer returning.
read article